Impaired Monocyte-Derived Dendritic Cell Phenotype in Prostate Cancer Patients: A Phenotypic Comparison With Healthy Donors Publisher Pubmed



Bakhshi P¹ ; Nourizadeh M² ; Sharifi L³ ; Nowroozi MR³ ; Mohsenzadegan M⁴ ; Farajollahi MM¹ Show Affiliations
Source: Cancer Reports Published:2024

Abstract

Background: Dendritic cells (DCs) play a crucial role in immunity. Research on monocyte-derived DCs (Mo-DCs) cancer vaccines is in progress despite limited success in clinical trials. This study focuses on Mo-DCs generated from prostate cancer (PCA) patients, comparing them with DCs from healthy donors (HD-DCs). Methods: Mo-DCs were isolated from PCA patient samples, and their phenotype was compared to HD-DCs. Key parameters included monocyte count, CD14 expression, and the levels of maturation markers (HLA-DR, CD80, CD86) were assessed. Results: PCA samples exhibited a significantly lower monocyte count and reduced CD14 expression compared to healthy samples (p ⟨ 0.0001). Additionally, PCA-DCs expressed significantly lower levels of maturation markers, including HLA-DR, CD80, and CD86, when compared to HD-DCs (p = 0.123, p = 0.884, and p = 0.309, respectively). Conclusion: The limited success of DC vaccines could be attributed to impaired phenotypic characteristics. These observations suggest that suboptimal characteristics of Mo-DCs generated from cancer patient blood samples might contribute to the limited success of DC vaccines. Consequently, this study underscores the need for alternative strategies to enhance the features of Mo-DCs for more effective cancer immunotherapies. © 2024 The Authors. Cancer Reports published by Wiley Periodicals LLC.